Indeed, the only process measures where RMC performed marginally under state and national average was among pneumonia patients receiving blood cultures, and heart failure/myocardial infarction patients receiving angiotensin converting enzyme inhibitor therapy. The gene discussed is ACE; the disease is susceptibility to pneumonia measurement.